Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease

Turkish Journal of Gastroenterology

Volumn 17, Issue 3, 2006, Pages 183-190

  Payzin, Bahriye ^a,c   Adakan, F Yeşim ^a   Yalçin, H Cahit ^a   Çetinkaya, Gulbin S ^a   Berkmen, Sibel ^a   Eraslan, Sibel ^b   Ünsal, Belkis ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Duzen Laboratories   (Turkey)

^c NONE   (Turkey)

Author keywords

Activated protein C resistance; Inflammatory bowel disease; Natural coagulation inhibitor protein; Thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; PROTEIN S; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GENE MUTATION; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PROTEIN DEFICIENCY; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TURKEY (REPUBLIC); ULCERATIVE COLITIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTHROMBIN TIME; REMISSION, SPONTANEOUS; TURKEY;

EID: 34147101791     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Novacek G, Miehsler W, Kapiotis S. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 685-90.
2. Liebman HA, Kashani N, Sutherland D. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115: 830-4.
3. Koutroubakis IE, Sfiridaki A, Mouzas UA. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 190-4.
4. Conlan M, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1089-93.
5. Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Cardiovasc Med. 2005; 2: 266-72.
6. Hudson M, Chitolie A, Hutton RA. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-7.
7. Sankey EA, Dhillon AP, Anthony A, et al. Early mucosal changes in Crohn's disease. Gut 1993; 34: 375-81.
8. Thompson NP, Wakefield JA, Pounder ER. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-15.
9. Koutroubakis IE. Unraveling the mechanisms of thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1325-7.
10. Mahmood A, Needham J, Prosser J, Mainwaring J. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005; 17: 739-44.
11. Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int J Colorectal Dis 2006; 13: 1-6.
12. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
13. Koster T, Rosendaal FR, de Ronde H. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
14. Larsen TB, Nielsen JN, Fredholm L, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002; 32: 92-6.
15. Turri D, Rosselli M, Simioni P, Tormone D. Factor V Leiden and prothrombotic gene mutation in inflammatory bowel disease in a Mediterranean area. Dig Liver Dis 2001; 33: 559-62.
16. Toruner M, Erkan O, Soykan I, et al. Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turk J Gastroenterol 2004; 15: 250-2.
17. Kader HA, Berman WF, Al-Seraihy AS, Ware RE. Prevalence of factor V G1691A (Leiden), prothrombin G20210A and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35: 629-35.
18. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-23.
19. Heneghan MA, Cleary B, Murray M. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci 1998; 43: 1356-61.
20. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
21. Chiarantini E, Valanzano R, Liotta AA, et al. Hemostatic abnormalities in inflammatory bowel disease. Throm Res 1996; 82: 137-46.
22. Hudson M, Hutton RA, Wakefield AJ. Evidence for activation of coagulation in Crohn's disease. Blood Coag Fibrinol 1992; 3: 773-8.
23. Seo M, Okada M, Tsuneyashi, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-5.
24. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 8: 514-5.
25. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanism and clinical applications. Ann NY Acad Sci 2005; 1051: 166-73.
26. Over-Hamzaoǧlu H, Abaci N, Ture F, et al. Prothrombotic gene mutations and Crohn's disease, is there any association? Hepatogastroenterology 2005; 52: 1467-9.
27. Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 1289-91.
28. Beauchamp NJ, Daly ME, Hampton KK, et al. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-22.
29. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haemetol 1996; 95: 579-86.
30. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
31. Gurgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. Turk J Pediatr 1997; 39: 313-5.
32. Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic test for factor V Leiden mutation. Br J Haemetol 1997; 97: 798-803.
33. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinolysis 1994; 5: 37-41.
34. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Q J Med 1997; 90: 183-8.
35. Helio T, Wartovaara U, Halme L. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 170-4.
36. Papa A, De Stefano V, Gasbarrini A, Chiusolo P. Prevalence of factor V Leiden and G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11: 499-503.
37. Over HH, Ulgen S, Tuglular T, et al. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998; 10: 827-9.
38. Yilmaz U, Ayaz S, Baysal Ç, Yildirim B. The importance of low level of free protein S in inflammatory bowel disease. Gastroenteroloji 1994; 5, 2: 300-4.
39. Stadnicki A, Bojko B, Myczkowska K. Selected risk factors of thrombotic complications in patients with ulcerative colitis. Wiad Lek. 2003; 56: 341-7.
40. Aadland E, Odegaard OR, Roseth A. Free protein S deficiency in patients with Crohn's disease. Scand J Gastroenterol 1994; 29: 333-5.
41. Aadland E, Odegaard OR, Roseth A. Free protein S deficiency in patients in chronic inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 957-60.
42. Saibeni S, Vecchi M, Valsecchi C, et al. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance and role of antiprotein S antibodies. Dig Dis Sci 2001; 46: 637-43.
43. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease. Response to therapy. Am J Dig Dis 1978; 23: 897-902.
44. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and sign of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-9.
45. Van Bodegraven A, Schoorl M, Baak J, et al. Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 487-92.
46. Knot E, Ten Cate JW, Leeksma OC, et al. No evidence for prethrombotic state in stable chronic inflammatory bowel disease. J Clin Pathol 1983; 36: 1387-90.
47. Stevens TRJ, James JP, Simmod NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-6.
48. Spannagl M, Dick A, Folwaczny C, et al. Factor V Leiden mutation in patients with inflammatory bowel disease. Gastroenterology 1999; 117: 280.